
Two to three weeks after treatment, the previously paralyzed mice began to walk. Credit: Lehrstuhl für Zellphysiologie
To date, paralysis resulting from spinal cord damage has been irreparable. With a new therapeutic approach, scientists from the Department for Cell Physiology at Ruhr-Universität Bochum (RUB) headed by Professor Dietmar Fischer have succeeded for the first time in getting paralyzed mice to walk again. The keys to this are the protein hyper-interleukin-6, which stimulates nerve cells to regenerate, and the way how it is supplied to the animals. The researchers published their report in the Journal Nature Communications from 15 January 2021.
When the communication breaks down
Spinal cord injuries caused by sports or traffic accidents often result in permanent disabilities such as paraplegia. This is caused by damage to nerve fibers, so-called axons, which carry information from the brain to the muscles and back from the skin and muscles. If these fibers are damaged due to injury or illness, this communication is interrupted. Since severed axons in the spinal cord can’t grow back, the patients suffer from paralysis and numbness for life. To date, there are still no treatment options that could restore the lost functions in affected patients.
Designer protein stimulates regeneration
In their search for potential therapeutic approaches, the Bochum team has been working with the protein hyper-interleukin-6. “This is a so-called designer cytokine, which means it doesn’t occur like this in nature and has to be produced using genetic engineering,” explains Dietmar Fischer. His research group already demonstrated in a previous study that hIL-6 can efficiently stimulate the regeneration of nerve cells in the visual system.
In their current study, the Bochum team induced nerve cells of the motor-sensory cortex to produce hyper-Interleukin-6 themselves. For this purpose, they used viruses suitable for gene therapy, which they injected into an easily accessible brain area. There, the viruses deliver the blueprint for the production of the protein to specific nerve cells, so-called motoneurons. Since these cells are also linked via axonal side branches to other nerve cells in other brain areas that are important for movement processes such as walking, the hyper-interleukin-6 was also transported directly to these otherwise difficult to access essential nerve cells and released there in a controlled manner.
Applied in one area, effective in several areas
“Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously,” points out Dietmar Fischer. “Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia.”
The research team is now investigating to what extent this or similar approaches can be combined with other measures to optimize the administration of hyper-Interleukin-6 further and achieve additional functional improvements. They are also exploring whether hyper-interleukin-6 still has positive effects in mice, even if the injury occurred several weeks previously. “This aspect would be particularly relevant for application in humans,” stresses Fischer. “We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Gene therapy
- BioMarin prices hemophilia gene therapy at nearly 29,000 euros per vial in Germany
The company has fixed the reimbursement amount for the therapy, Roctavian, with the German National Association of Statutory Health Insurance Funds, Germany's primary public health insurance body. The ...
- Hope, devastation, and finally, a treatment: One family’s road to gene therapy for Duchenne muscular dystrophy
A family in Wilmington, Delaware, faced a looming deadline to get their son a new gene therapy treatment for Duchenne muscular dystrophy.
- ‘Silicon Valley’ in Philadelphia, USA… Cell and Gene Therapy, Building an Ecosystem.
Philadelphia, Pennsylvania, USA, is currently the hottest place in the world for cell and gene therapy (CGT), an emerging therapeutic field. Driving two hours from New York City into Pennsylvania's ...
- Decision looms for landmark gene-editing therapy
The FDA is expected to decide by the end of next week whether to approve the first gene-editing therapy in the U.S., just weeks after the treatment for a rare genetic blood disorder received ...
- BCS Financial Leading the Way with New Gene Therapy Reinsurance Solutions
New solutions aim to improve access to growing gene therapy pipeline by financing and mitigating health payer risk CHICAGO, Nov. 28, 2023 /PRNewswire/ -- BCS Financial has expanded its stop loss and ...
Go deeper with Google Headlines on:
Gene therapy
[google_news title=”” keyword=”gene therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Designer cytokine
- How to Reduce Cytokines: 12 Steps
Cytokines are small proteins that play a crucial role in the immune system, acting as messengers between cells to regulate inflammation and the body’s response to infection. Sometimes, the production ...
- Cytokine loops driving senescence
Unexpected findings now identify multiple secreted inflammatory cytokines, their cognate receptors and positive-feedback loops with corresponding transcription factors, as key mediators of both ...
- Cytokines and systemic lupus erythematosus
Many cytokines have been implicated in regulating disease activity and in the involvement of different organs in patients with SLE. This article reviews both the role of individual cytokines and ...
- Common Gamma-Chain Cytokines & Receptors
The γc subunit binds with these different cytokine-specific receptor subunits to form unique heterodimeric receptors for IL4, IL7, IL9, and IL21, or heterotrimeric receptors for IL2 or IL15, ...
- Cytokine receptor
Key steps of the JAK-STAT pathway for type 1 and 2 cytokine receptors Signal transduction. (Cytokine receptor at center left.) In recent years, the cytokine receptors have come to demand the attention ...
Go deeper with Google Headlines on:
Designer cytokine
[google_news title=”” keyword=”designer cytokine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]